Ultralife Corporation Reports Fourth Quarter 2025 Financial Results

Key Highlights

• Sales Surge: Ultralife Corporation reported fourth quarter sales of \$48.5 million, representing a robust increase compared to \$43.9 million in the same quarter of 2024.
• Improved Gross Profit: Gross profit rose to \$12.1 million (24.9% of revenue) from \$10.6 million (24.2% of revenue) in Q4 2024, indicating improved profitability margins.
• Operating Performance: Despite revenue and gross profit growth, the company reported an operating loss of (\$10.6 million) in Q4 2025, down from an operating income of \$1.47 million in Q4 2024.
• Net Loss: Net loss attributable to Ultralife Corporation was (\$7.42 million), translating to a loss per share of (\$0.45) (basic and diluted).
• Adjusted EBITDA: The company reported Adjusted EBITDA of \$5.68 million for the quarter, a key non-GAAP measure used by management to evaluate operating performance.
• Balance Sheet Strength:
  • Cash: \$9.35 million (up from \$6.85 million a year ago)
  • Total Assets: \$216.91 million
  • Shareholders’ Equity: \$130.13 million
  • Treasury Stock: (\$21.49 million)
• Conference Call: Ultralife held its earnings call on March 10, 2026, at 8:30 AM ET, with investor access via pre-registration and webcast.

Detailed Financial Analysis

Ultralife Corporation’s Q4 2025 report showed strong revenue growth, with sales increasing by over 10% year-on-year. This growth was accompanied by a higher gross profit margin, suggesting effective cost management or improved pricing power. However, the operating loss of \$10.6 million is a significant reversal from the prior year’s operating income, raising concerns about increased operating expenses or other factors impacting profitability.

The net loss of \$7.42 million (or \$0.45 per share) is a substantial negative, and could be price sensitive, as it indicates a deterioration in bottom-line performance despite revenue gains. Shareholders should note that the loss is also reflected in both basic and diluted per-share calculations, suggesting no offset from dilution effects.

The company’s balance sheet remains strong, with increased cash reserves and substantial equity. The presence of treasury stock and capital in excess of par value indicates ongoing capital management efforts. Notably, intangible assets decreased significantly from \$24.56 million to \$10.93 million, which may signal impairments or write-downs that could affect future earnings.

Adjusted EBITDA of \$5.68 million provides a non-GAAP perspective on operating performance, excluding non-recurring items, interest, taxes, depreciation, amortization, and stock-based compensation. This metric is positive and may reassure investors about core business profitability, but it does not offset the GAAP net loss.

The report also confirms that Ultralife is not an emerging growth company and is not subject to extended transition periods for accounting standards, which means it is fully compliant with current financial regulations.

Shareholder and Investor Considerations

• Price Sensitivity: The net loss and operating loss in the face of revenue growth are likely to be price sensitive and may impact the share value negatively, especially if investors expected profitability to accompany sales growth.
• Asset Impairment: The sharp reduction in intangible assets may indicate impairment charges, which are important for future earnings and could be material to share price.
• Adjusted EBITDA: A positive Adjusted EBITDA suggests underlying business strength, but the gap between EBITDA and GAAP earnings warrants further investor scrutiny.
• Balance Sheet: Solid cash and equity positions may provide comfort regarding liquidity and solvency, but sustained operating losses can erode these strengths over time.
• Future Outlook: Management’s commentary and future guidance (not included in this summary) should be monitored closely. Investors are cautioned to review the company’s forward-looking statements, as factors such as global conflicts, weather, or other external risks may affect future performance.

Contacts

Company Contact: Philip A. Fain, Ultralife Corporation ([email protected], (315) 210-6110)
Investor Relations Contact: Jody Burfening, Alliance Advisors IR ([email protected], (212) 838-3777)

Disclaimer

This article is based on Ultralife Corporation’s official SEC filings and accompanying press release for the fourth quarter ended December 31, 2025. The information herein is provided for informational purposes only and does not constitute investment advice. Investors should review the full report and consult with their own advisors before making any investment decisions. Ultralife Corporation’s performance is subject to a range of risks and uncertainties, and past results are not necessarily indicative of future performance. The company undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances.

View ULTRALIFE CORP Historical chart here